

BASO

The need or new guidelines



BASO

- Founded in 1988
 - Need to assemble the researchers in the field of obesity
 - Need to assemble all health care providers that treat patients suffering from obesity
 - Lobby to improve clinical care for obese patients
 - Lobby to improve the means for research to prevent and treat obesity



Obesity Academy targets the first line

BASO

- President: Bart Van der Schueren (Endocrinologist, UZLeuven/KULeuven)
- Vice-president: Jean-Paul Thissen (Endocrinologist, St Luc/UCL)
- Treasurer: Matthias Lannoo (Abdominal Surgeon, UZLeuven/KULeuven)
- Secretary: Marie Baréa (Dietitian, Erasme/ULB)

Board members:

- Véronique Beauloye (Pediatrician, St Luc/UCL),
- Roland Devlieger (Gynecologist/obstetrician, UZLeuven/KULeuven)
- Dirk Vissers (Physiotherapist, UZA/UA)
- An Verrijken (Dietitian, UZA/UA),
- Eveline Dirinck (Endocrinologist, UZA/UA),
- Inge Gies (Pediatrician, UZBrussel/VUB),
- Barbara Lembo (Psychologists, Claire Vallons)



Nutrition, Physical Activity and Obesity Belgium



World Health
Organization

REGIONAL OFFICE FOR Europe



This is one of the 53 country profiles covering developments in nutrition, physical activity and obesity in the WHO European Region. The full set of individual profiles and an overview report including methodology and summary can be downloaded from the WHO Regional Office for Europe website: <http://www.euro.who.int/en/nutrition-country-profiles>.

© World Health Organization 2013
All rights reserved.

DEMOGRAPHIC DATA

Total population	10 712 000
Median age (years)	41.2
Life expectancy at birth (years) female male	82.5 77.0
GDP per capita (US\$)	46 469.0
GDP spent on health (%)	10.7

Monitoring and surveillance Overweight and obesity in three age groups


Adults (18/20 years and over)

Intercountry comparable overweight and obesity estimates from 2008 (1) show that 56.4% of the adult population (≥ 20 years old) in Belgium were overweight and 22.1% were obese. The prevalence of overweight was higher among men (63.4%) than women (49.9%). The proportion of men and women that were obese was 23.3% and 21.0%, respectively.

National data from 2008 show that 47% of the adult population aged 18 years and over in Belgium were overweight (33% pre-obesity and 14% obesity). The prevalence of overweight was higher among men (54%) than women (40%). No difference for obesity was found between men and women. It should be taken into account that these national data do not allow for comparability across countries (2).

Adulthood obesity prevalence forecasts (2010–2030) predict that in 2020, 13% of men and 14% of women will be obese. The model predicts that by 2030, 15% of men and 14% of women will be obese.


PREVALENCE OF OVERWEIGHT AND OBESITY (%) AMONG BELGIAN ADULTS BASED ON WHO 2008 ESTIMATES




Source: WHO Global Health Observatory Data Repository (1).



Obesity




Trends in obesity from selected countries





Obesity = simple Solution





Hippocrates circa 400BC

"Let food be your medicine
and medicine be your food"



Obesity = complex

◆ Factors

=>

Consequences

Map 0
Full Generic Map




The need for new guidelines



The need for new guidelines

New treatments



Figures from Dr Gallo's presentation "Regelgeving rond selectcriteria en terugbetaling bariatric" 12/10/2012

* Extrapolation based on 1st semester 2012 vs 1st semester 2011

The need for new guidelines

New treatments

[Full Prescribing Information](#) | [Medication Guide](#) | [Enroll](#) | For Health Care Professionals: [REMS](#) | [SaxendaPro.com](#)

**Saxenda**
liraglutide injection 3mg

Selected Important Safety Information
What is the most important information I should know about Saxenda®?
Serious side effects may happen in people who take Saxenda®, including:
Possible thyroid tumors, including cancer. Tell your health care professional if
[Show More](#)

[Home](#) | [About Saxenda®](#) | [How to Use Saxenda®](#) | [Co-pay & Savings](#) | [Info & Tools](#) | [SaxendaCare®](#)

Need Help Taking Off Excess Weight and Keeping It Off?

You have tried for years. Countless unhealthy diets. Short-term exercise fads. Endless frustration. It's no longer about finding a quick fix—it's about focusing on your ongoing weight loss.



Saxenda® is an FDA-approved, prescription injectable medicine that, when used with a low-calorie meal plan and increased physical activity, may help some adults with excess weight^a who also have weight-related medical problems (such as high blood pressure, high cholesterol, or type 2 diabetes), or obesity,^b to lose weight and keep it off.

Saxenda® is not for the treatment of type 2 diabetes and should not be used with Victoza® or any other GLP-1 receptor agonist or insulin. It is not known if Saxenda® is safe and effective when taken with other prescription, over-the-counter, or herbal weight-loss products. [Click here for additional Limitations of Use.](#)

Be sure to [look up your co-pay](#) and ask your health care professional if Saxenda® is right for you.



Learn About Saxenda® Benefits

**Know Your Saxenda® Co-pay**
Find out your co-pay or if Saxenda® is covered for you before getting your prescription.
[Look up your co-pay →](#)

**Savings and SaxendaCare®**
Print or activate your Saxenda® Savings Card and gain instant access to SaxendaCare®.
[Get started →](#)


Already activated your Saxenda® Savings Card, but haven't enrolled in SaxendaCare® yet?
[Join now! →](#)

**Is Saxenda® Right for You?**
Answer a few questions to find out if you should talk to your health care professional about Saxenda®.
[Get your personal assessment →](#)

**For Health Care Professionals**
Risk Evaluation and Mitigation Strategy (REMS)
[Learn more →](#)

The need for new guidelines

New Problems



The need for new guidelines


New Problems



Tipping the scales

Tipping the scales

Most effective obesity interventions, estimated Disability-Adjusted Life Years* saved in Britain, m



Source: McKinsey

*Years of life lost to ill health, disability and early death, over lifetime of 2014 population

The economist: the war on obesity

